ClinicalTrials.gg

Program

xeruborbactam

Also written as “Cefiderocol/Xeruborbactam”, “Xeruborbactam” and “Xeruborbactam/Cefiderocol”.

Its studies are mostly in Bacterial Infections, led by Shionogi.

Furthest: phase 1, since Aug 2, 20243 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi30 open or runningphase 1since Aug 2, 2024Aug 2, 2024none ahead

Also a collaborator on its studies: shionogi-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 2, 2024First study: phase 1 study in Bacterial InfectionsFirst studyNCT06547554 · 60 enrolled · United States
  2. Jul 11, 20252 phase 1 studiesNCT07083817, NCT07104162

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07104162Bacterial Infections · United States1CompletedSep 4, 202640
NCT07083817ADME · United Kingdom1CompletedAug 27, 20258
NCT06547554Bacterial Infections · United States1CompletedOct 27, 202560

How it is read

Names in the registry

  • “Cefiderocol/Xeruborbactam”, 1 entry
  • “Xeruborbactam”, 1 entry
  • “Xeruborbactam/Cefiderocol”, 1 entry
  • “[14C]Xeruborbactam”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.